Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accounts Payables (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Accounts Payables for 9 consecutive years, with $11.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 673.41% year-over-year to $11.0 million, compared with a TTM value of $11.0 million through Sep 2025, up 673.41%, and an annual FY2024 reading of $2.0 million, up 1811.65% over the prior year.
  • Accounts Payables was $11.0 million for Q3 2025 at Autolus Therapeutics, up from $5.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $11.0 million in Q3 2025 and bottomed at $103000.0 in Q4 2023.
  • Average Accounts Payables over 5 years is $2.4 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Accounts Payables tumbled 80.95% in 2021, then skyrocketed 1811.65% in 2024.
  • Year by year, Accounts Payables stood at $431000.0 in 2021, then increased by 23.2% to $531000.0 in 2022, then plummeted by 80.6% to $103000.0 in 2023, then surged by 1811.65% to $2.0 million in 2024, then skyrocketed by 456.98% to $11.0 million in 2025.
  • Business Quant data shows Accounts Payables for AUTL at $11.0 million in Q3 2025, $5.4 million in Q2 2025, and $4.5 million in Q1 2025.